SMALL-MOLECULE THERAPUTICS MULTI-PARAMETER DRUG DISCOVERY FOR REAL-WORLD SUCCESS

Critical Challenge
in Drug Development

Small molecules account for nearly 60% of the global pharma market, yet <10% of candidates entering clinical trials reach approval.

With rising development costs and longer approval timelines, the industry urgently needs smarter tools to design highly optimized, novel molecules that meet multiple pharmacological, chemical, and safety criteria from the start.

Our Solution

ChemPass AI designs truly novel and viable small molecules optimized for both efficacy and developability, dramatically increasing the probability of clinical success.

90% of molecules generated during Discovery & Optimization meet all predefined parameters

DIVERSE partnership models

Evogene actively partners with biotech and pharmaceutical companies to expand its therapeutic pipeline across multiple domains – including oncology, neurology, inflammation, and molecular glues.

Joint discovery projects for co-developing new chemical entities (NCEs)

Collaborative R&D programs integrating ChemPass AI into partners’ internal discovery workflows

Licensing and co-commercialization of validated molecular leads

TAILORED & OPTIMIZED FOR SUCCESS

chempass ai
  • Literature search, data preprocessing and target modeling
  • Identify potential hits using PointHit
  • Identify elaborated 
analogs using ActiveSearch
  • Generate novel leads using LeadOptGPT
  • Target Preprocessing
  • Hit Screening
  • Hit-To-Lead
  • Lead Optimization
partner / internal expertise
  • Target elucidation and biological interpretation
  • Purchase hits and test activity and selectivity
  • Purchase analogs and test activity and selectivity
  • Synthesis of novel leads 
and validation

EXAMPLE COLLABORATIONS

Prof. Ehud Gazit, Tel Aviv University – New Therapeutics for Metabolic Diseases

We partnered with Professor Ehud Gazit, a world-renowned expert in molecular self-assembly and metabolic disorders, to design novel small molecules that inhibit pathological self-assembly processes. This breakthrough approach has the potential to treat diseases such as Tyrosinemia, Gout, and Maple Syrup Urine Disease (MSUD).

By combining Evogene’s ChemPass AI with Professor Gazit’s expertise in molecular mechanisms, the partnership creates a discovery process uniquely positioned to develop new classes of small-molecule therapeutics for severe metabolic diseases.

Novel Molecular Glue Biotech Discovery Partnership

Using a molecular glue approach, this partnership aimed to tackle protein–protein interactions (PPIs), which represent one of the most complex and promising frontiers in drug discovery, but are notoriously hard to target using traditional small molecules.

We were able to show that ChemPass AI generated 150 novel molecular glue candidates targeting a specific PPI. These molecules contain 100% novel scaffolds, not found in public databases or patents. Additionally, they showed 93% uniqueness and 92% chemical validity, and strikingly 6× improvement in binding prediction accuracy over standard models.

Emphasizing Partnership Opportunity
Shaping the Future of Drug Discovery — Together

neurology
oncology
Cardiology
metabolic disorders
rare diseases
others
immuno- modulators
analgesics
enzyme
ppi modulators
covalent inhibitors
ion channels
degraders
molecular glues

Partner with Evogene
to accelerate your next small‑molecule breakthrough

From target to optimized lead with higher probability of clinical success.